Pramlintide: Mechanism, Research & UK Safety Profile
Also known as: Symlin, AC137
Synthetic amylin analogue FDA-approved in the US (Symlin) as an adjunct to mealtime insulin in type 1 and type 2 diabetes. Not currently MHRA-licensed in the UK. Pharmacological predecessor to the modern cagrilintide programme.
Molecular formula
C171H267N51O53S2
Molecular weight
Approx. 3.7 kDa (37-amino-acid peptide)
Half-life
Approximately 48 minutes; necessitates 2–3 times daily prandial injection.
Category
Amylin analogue
Overview
Pramlintide (Symlin) is a 37-amino-acid synthetic analogue of human amylin, a pancreatic peptide co-secreted with insulin from beta cells in response to meals. Native amylin aggregates and cannot be formulated for injection; pramlintide incorporates substitutions at positions 25 (asparagine → alanine), 28 (serine → alanine) and 29 (serine → proline) that prevent self-aggregation while preserving receptor binding. Pramlintide is FDA-approved in the United States (AstraZeneca / Amylin Pharmaceuticals, brand Symlin) as an adjunct to mealtime insulin for adults with type 1 diabetes and type 2 diabetes who have not achieved adequate glycaemic control despite optimised insulin therapy. It is not currently licensed by the MHRA for use in the UK; European Medicines Agency approval was pursued and historically withdrawn. Pramlintide is an important pharmacological predecessor to the modern long-acting amylin analogue programme, most notably cagrilintide.
Discovery & Research History
Human amylin was characterised in the 1980s in islet amyloid deposits from patients with type 2 diabetes. The observation that amylin was co-secreted with insulin and appeared to contribute to postprandial glycaemic regulation prompted interest in therapeutic analogues. Amylin Pharmaceuticals (later acquired by AstraZeneca) developed pramlintide as the first drug in the amylin analogue class. The compound received FDA approval in 2005 for adjunctive mealtime use alongside insulin in type 1 and type 2 diabetes. European regulatory progress did not result in a lasting EMA licence; the MHRA has not licensed pramlintide in the UK. The subsequent generation of amylin analogues — principally cagrilintide (Novo Nordisk) — drew on the mechanistic precedent of pramlintide, engineering fatty-acid acylation for once-weekly albumin binding rather than the 2–3 times daily injection schedule pramlintide requires.
Mechanism of Action
Pramlintide acts as an agonist at amylin receptors, which are members of the calcitonin receptor family assembled with receptor activity-modifying proteins (RAMPs). AMY1R, AMY2R and AMY3R are formed by the calcitonin receptor (CTR) complexed with RAMP1, RAMP2 and RAMP3 respectively. Key pharmacological effects include: slowing of gastric emptying, which blunts the rate of postprandial glucose absorption; suppression of postprandial glucagon release from alpha cells; and activation of satiety signalling via the area postrema and nucleus tractus solitarius in the hindbrain. These effects are complementary to insulin action and are blunted or absent in people with type 1 or advanced type 2 diabetes because amylin deficiency parallels insulin deficiency. The short half-life of approximately 48 minutes necessitates injection immediately before meals.
Researched Effects
- Reduction in postprandial glucose excursions as an adjunct to mealtime insulin in type 1 and type 2 diabetes (primary FDA-approved indication).
- Modest reduction in HbA1c when used as adjunct to optimised insulin therapy.
- Reduction in total daily insulin dose and body-weight reduction in some trial cohorts.
- Established pharmacological proof-of-concept for the amylin-receptor axis as a therapeutic target, underpinning the cagrilintide programme.
Theoretical Research Protocols
- Dosage range
- Trial-arm doses published in the primary literature are research records only. This page is not a prescribing or self-administration guide. Refer to published primary trial reports for the dosing arms studied.
- Frequency
- Injected subcutaneously immediately before each main meal (2–3 times daily) in the FDA-approved indication. The short half-life necessitates prandial dosing.
- Duration
- Continuous adjunctive use alongside mealtime insulin in the approved indication; trial durations vary. See primary publications.
- Administration routes
- Subcutaneous injection (pre-meal)
Safety Profile
Common side effects (research)
- Nausea (most frequently reported, particularly at treatment initiation; typically transient).
- Vomiting.
- Hypoglycaemia risk increased when combined with mealtime insulin — dose adjustment of insulin may be required.
- Injection-site reactions (typically mild).
- Anorexia / appetite reduction.
Rare risks
- Severe hypoglycaemia (particularly in type 1 diabetes when co-administered with insulin without appropriate dose titration).
- Interaction with drugs that slow gastric motility.
Contraindications
- Hypoglycaemia unawareness (contraindicated in the approved labelling).
- Poor compliance with current insulin or glucose self-monitoring regimen.
- Hypersensitivity to pramlintide or excipients.
- Conditions requiring rapid gastric emptying (gastroparesis).
- Use in the UK is not applicable as the product is not MHRA-licensed.
UK Regulatory Status
United Kingdom (MHRA): Not currently licensed by the MHRA for any human therapeutic indication. Pramlintide does not hold a UK marketing authorisation at the time of review.
European Union (EMA): EMA approval pursued historically; not currently EMA-licensed at the time of review.
Notes: Pramlintide (Symlin) holds FDA approval in the United States as an adjunct to mealtime insulin in type 1 and type 2 diabetes. UK access is jurisdiction-dependent; UK clinicians and patients cannot access pramlintide through a standard MHRA-licensed pathway. Any clinical access in the UK would require appropriate specialist and regulatory engagement.
Related research resources
Key Research Studies
Ratner RE et al. Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes. Diabetes Care 2002;25(4):724–730.
Pivotal trial demonstrating that pramlintide as an adjunct to insulin improved HbA1c and reduced body weight compared with placebo in adults with type 2 diabetes.
Whitehouse F et al. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care 2002;25(4):724–730.
Long-term evaluation of pramlintide as adjunctive therapy in type 1 diabetes, reporting reductions in HbA1c and postprandial glucose excursions.
Younk LM et al. Pramlintide and the treatment of diabetes: a review of the data since its introduction. Expert Opin Pharmacother 2011;12(9):1439–1451.
Narrative review summarising the clinical evidence base for pramlintide as adjunctive insulin therapy in type 1 and type 2 diabetes since FDA approval.
Frequently Asked Questions
What is pramlintide?
Pramlintide (Symlin) is a synthetic analogue of the pancreatic hormone amylin, approved by the FDA in the United States as an adjunct to mealtime insulin in type 1 and type 2 diabetes. It slows gastric emptying, suppresses postprandial glucagon and signals satiety via the area postrema.
Is pramlintide licensed in the UK?
No. Pramlintide is not currently licensed by the MHRA for any human therapeutic indication. It holds FDA approval in the US as Symlin, but it does not hold a UK marketing authorisation. UK access would require appropriate specialist and regulatory engagement.
How is pramlintide related to cagrilintide?
Pramlintide is the first-generation amylin analogue and established the pharmacological proof-of-concept for amylin-receptor agonism in diabetes and weight management. Cagrilintide (AM833, Novo Nordisk) is a next-generation amylin analogue engineered with fatty-acid acylation for once-weekly albumin-bound dosing, overcoming pramlintide's short half-life that requires 2–3 daily injections.
Why does pramlintide need to be injected before every meal?
Pramlintide has a half-life of approximately 48 minutes. It must be injected subcutaneously immediately before each main meal to match the postprandial window during which amylin effects (slowing gastric emptying, suppressing glucagon) are pharmacologically relevant.
Related trials
No published trials yet linked to this page. Source verification required.